Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
2-(3-cyano-4-(2-(methyl-d3)propoxy-1,1,2,3,3,3-d6)phenyl)-4-methylthiazole-5-carboxylic acid
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Febuxostat-d9 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Febuxostat-d9 usage and description
Febuxostat D9 is a deuterated analog of Febuxostat, which is a potent and selective inhibitor of xanthine oxidase, an enzyme that plays a key role in the production of uric acid in the body. Febuxostat D9 is a labeled compound that is commonly used as an internal standard in pharmacokinetic and bioanalytical studies to facilitate quantification of Febuxostat in biological samples.
Febuxostat D9 is an orally-administered medication that is primarily used for the prevention and treatment of hyperuricemia in patients with gout. It works by blocking the activity of xanthine oxidase, which reduces the production of uric acid in the body. This helps to prevent the formation of urate crystals, which can cause inflammation and damage to joints and other tissues.
The chemical name of Febuxostat D9 is 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid-d9. Its molecular formula is C16H8D9N3O2S, and its molecular weight is 327.49 g/mol. It is a white to off-white crystalline powder that is sparingly soluble in water.
Febuxostat D9 undergoes extensive hepatic metabolism, primarily via glucuronidation and oxidation, and is excreted primarily in the feces. It has a half-life of approximately 5-8 hours in humans. The recommended dosage for Febuxostat D9 varies depending on the specific condition being treated and the individual patient's medical history and response to treatment. As with any medication, it is important to follow the prescribing physician's instructions and to report any adverse effects or concerns.
